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Abstract 
 
Eg5, a mitotic kinesin exclusively involved in the formation and function of the mitotic spindle has 
attracted interest as an anticancer drug target. Eg5 is co-crystallized with several inhibitors bound 
to its allosteric binding pocket. Each of these occupies a pocket formed by loop 5/helix α 2 
(L5/α2). Recently designed inhibitors additionally occupy a hydrophobic pocket of this site. The 
goal of the present study was to explore this hydrophobic pocket with our MED-SuMo fragment 
based protocol, and thus discover novel chemical structures that might bind as inhibitors. The 
MED-SuMo software is able to compare and superimpose similar interaction surfaces upon the 
whole PDB. In a fragment based protocol, MED-SuMo retrieves MED-Portions that encode 
protein-fragment binding sites and are derived from cross-mining protein-ligand structures with 
libraries of small molecules. We have excluded intra-family MED-Portions derived from ligands 
that occupy the hydrophobic pocket and predicted new potential ligands that would fill 
simultaneously both pockets. Some of the latter are identified in libraries of synthetically 
accessible molecules by the MED-Search software. 
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PDB Protein Data Bank 
KSP Kinesin Spindle Protein 
HYD Hydrophobic  
L5/α2 loop 5/helix α 2 
Å Angström 
Du MED-Portion dummy atom 
 
 
Introduction 
 
During metaphase, the mitotic spindle maintains a constant shape and size though 
their principal constituent, the microtubules are continuously being polymerized, 
depolymerized and transported towards the two spindle poles [1-3]. Motor 
proteins from the kinesin family are involved in the mitotic spindle assembly, as 
well as an important number of cellular processes such as intracellular vesicles 
transport, chromosome segregation, cell division and motility in a tight 
collaboration with proteins of the cytoskeleton tubulin and actin [4, 5]. 
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Inhibition of the mitotic spindle formation is an interesting target in cancer 
chemotherapy. Anti-mitotic agents used to date for cancer treatment, target 
microtubule stability (e.g., Vinca alkaloids and taxanes). They cause serious side-
effects, such as neurotoxicity (reviewed in [6]). Furthermore the development of 
resistance against these anti-mitotic agents restricts their application. 
 Another approach to inhibit the mitotic spindle formation has emerged. 
This alternative acts by inhibiting the mitotic motors that interact with 
microtubules [7]. Eg5 (also known as Kinesin Spindle Protein, KSP, or kinesin-
5s) has emerged from recent studies as a leading candidate for targeted anti-
mitotic therapies. This kinesin is exclusively involved in the formation and 
function of the mitotic spindle, by driving a relative sliding of microtubules in the 
mitotic spindle (for review see [8]). The inhibition of Eg5 leads to cells with 
monopolar spindles (monaster) during mitosis, resulting in a cell cycle arrest and 
apoptosis, without interfering with other microtubule dependent processes. 
Several small molecules are now known that inhibit human Eg5 by binding to its 
catalytic motor domain. These discoveries are attracting a potential interest in this 
protein as an anticancer drug target. 
The first inhibitor discovered by the groups of Stuart Schreiber and Tim 
Mitchison is a small cell permeable molecule, monastrol [7]. One year after the 
resolution of the structure of the unbound Eg5 [9], the structure of the Eg5 bound 
to monastrol was also solved [10]. Monastrol binds specifically to the Eg5 and 
allosterically inhibits the ATPase activity of the kinesin. Further studies brought 
several inhibitors into clinical trials and several structures of the Eg5 with diverse 
types of inhibitors are now solved (Figure 1) [11-16]. Most of these inhibitors 
interact with an hydrophobic (HYD) pocket that is inoccupied by the monastrol 
(Figure 2). This difference in the binding mode results in a ten fold increase of the 
affinity in the case of the monastrol and its homologue mon-97 (PDB code 2ieh): 
(S)-monastrol inhibits the basal ATPase activity with an IC
50
 value of 1.7 µM, 
whereas the (R)-mon-97 has an IC
50
 value of 110 nM [17]. The current knowledge 
of the available inhibitors for this target enlarges the scope for rational drug 
design approaches to discover more potent inhibitors for the Eg5. 
 The SuMo software was originally developed to detect structural 
similarities between proteins, in particular protein binding sites [18]. MED-SuMo, 
the commercially available version for drug design applications, is able to detect 
potential binding sites, characterize an unknown protein binding site and probe 
active-site selectivity within a protein family. In MED-SuMo, all chemical groups 
that can make interactions with other molecules are represented by Surface 
Chemical Features (SCFs) such as hydrogen-bond donor and acceptor, aromatic 
group, hydrophobic group, and so forth. Once detected, all neighboring SCFs are 
grouped in triplets which represent nodes of a graph encoding the protein 
interacting surface. The graph is then compared to a precompiled database of 
similarly constructed graphs (Figure 3, [18, 19]). MED-SuMo is extremely 
efficient, allowing application to the entire PDB, and therefore maximizing the 
probability of finding relevant local similarities on the protein binding site [18-
22]. The number of macromolecular structures publicly available from the Protein 
Data Bank (PDB) is raising quadratically, with 7 065 structures deposited in 2008 
and more than 500 new entries currently released every month. In total, more than 
55 000 macromolecule structures are accessible as of January 27th, 2009 
(http://www.rcsb.org/pdb/statistics). 
 Recently, we developed a fragment based drug design approach based on 
MED-SuMo/MED-Fragmentor/MED-Hybridise technologies [21]. For this new 
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approach, the MED-Fragmentor software component was designed to generate a 
MED-SuMo database of MED-Portions describing local protein-fragment 
interactions by cross-mining the PDB and a chemical library of small molecules. 
The MED-Portions are defined by several criteria including chemical moiety 
represented in 3D and the corresponding SCF environment. Local graph 
similarities are found using the MED-SuMo algorithm thus retrieving from the 
database MED-Portions aligned in 3D to the query structure. These MED-
Portions can be combined using their 3D coordinates with the MED-Hybridise 
software. 
 
The goal of this study was to design inhibitors of Eg5 by populating the HYD 
pocket of the allosteric binding site. Our fragment-based protocol is applied to 
populate the HYD pocket with chemical moieties of inter-family MED-Portions 
that MED-SuMo retrieves by local similarity search upon the whole PDB. Intra-
family MED-Portions are discarded to bias towards the generation of new ligands 
compared to the known kinesin PDB ligands. The retrieved MED-Portions were 
combined using the MED-Hybridise software and 3D substructure filtering rules 
to focus on the most promising hybrids having similar binding mode to known 
inhibitors. This protocol allowed us to generate hybrid molecules that can be new 
potential ligands, among which, a certain number can be retrieved by MED-
Search software in publicly available chemical libraries, ChemBridge, Maybridge, 
and PubChem database [23-25]. 
 
 
Results and discussion 
 
Definition of the custom SCF dictionary 
Several water molecules are observed in the allosteric binding site of Eg5, 
especially inside the HYD pocket. The default MED-SuMo dictionary does not 
consider these molecules for the graph generation of the binding site. They could 
however bring important structural information, when they are involved in 
hydrogen bond bridging the ligand and the protein target. We therefore decided to 
add H-bond donors and H-bond acceptors on the water molecules defined in the 
PDB file. As a result these can be superposed with the H-bond donors and 
acceptors on either the water molecules or the protein SCFs. Since the graph 
generation of the database is done at 4.5 Å around the ligand, only the water 
molecules in the near neigbourhood of the ligand are taken into account, those 
mostly involved in H-bond interactions. 
 With this modified dictionary each binding site is defined by a larger 
number of SCFs, since water molecules can be considered as H-bond donors or 
acceptors. In addition the SCFs that are already engaged in intra-protein H-bond 
are not eliminated, resulting in formation of graphs containing a greater number of 
triplets. For example, for the query defined by any protein atom at 10 Å around 
monastrol (NAT ligand) in the 1x88 structure [26], 125 SCFs are considered in 
the default database and form 3 918 triplets, compared to the modified dictionary 
database where 187 SCFs are considered and form 6 090 triplets. This increasing 
number of SCF in query signature results generally in hits having larger number 
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of SCFs and by consequence with greater MED-SuMo score [27]. In this work, all 
H-bond donors and acceptors SCFs are chemical features without any specified 
orientation. 
 This new SCF dictionary is able to better detect conserved secondary 
structures surrounding binding site, and to better populate the binding sites or 
surfaces where water molecules are present. An inconvenient consequence is that 
some of the SCFs considered are already engaged in an H-bond and could not 
interact with MED-Portions chemical moieties. This approximation seems to be 
better than removing them because backbone carbonyl and NH can be involved in 
two H-bonds, one intra-protein and one with a water molecule. Nonetheless, we 
are able to retrieve with this modified dictionary database with additional 
pertinent MED-Portions (data not shown). 
 
Choice of the Query structure and selection of collected MED-
Portions 
In order to predict new categories of inhibitors that could fill the HYD pocket, we 
have chosen to use a structure containing an inhibitor that does not fill the HYD 
pocket. We constructed the query at 10 Å around monastrol of the 1x88 entry in 
the PDB. The query is then submitted to MED-SuMo to be compared to the 
MED-Portions database built with the new dictionary described above (Figure 4). 
During MED-SuMo comparison an automatic calculation of steric clashes 
between query protein and retrieved MED-Portions chemical moieties has been 
done (as described in Background and methods). We kept only the MED-Portions 
chemical moieties that possessed fewer than 10 bumps with the query once 
superimposed inside its binding pocket. To show that the protocol is capable of 
exploring the HYD pocket with inter-family MED-Portion chemical moieties, we 
have eliminated all the MED-Portion chemical moieties that are directly derived 
from co-crystallized ligands of Eg5 that are targeting this pocket (Figure 2, see 
Background and Methods for detailed description). The retained MED-Portions  
(1092 MED-Portions chemical moieties) constitute the starting point for the next 
steps. 
 
Hybridization and filtering of the MED-Portions into potential ligands 
The retained MED-Portions chemical moieties were subjected to five 
hybridization and filtering steps with MED-Hybridise software [21]. 
Hybridization of all the MED-portions would produce a very large number of 
hybrids. Here we focused the hybrid generation by targeting the HYD pocket. At 
the same time the hybrids have been selected to keep interactions with the L5/α2 
pocket to mimic the known inhibitors binding. 
To do so a sublist of rings populating one or the other pockets, called 
‘seeds’, has been selected from the MED-Portions (Figure 5, 83 in the HYD 
pocket, 153 in the L5/α 2 pocket, see Background and methods for detailed 
description). The first step consisted of the hybridisation of these ‘seeds’ with the 
whole list of MED-Portions chemical moieties using our Chain Combine 
algorithm of MED-Hybridise (described in [21]). At each following step the 
‘seeds’ were hybridised to the original MED-Portions and the hybrids generated 
during the previous step. During each hybridisation step exact 3D duplicates 
(same chemical structure and same 3D coordinates) are discarded.  
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In addition we applied a 3D sub-structure filter keeping only the hybrids 
that explored either the HYD or the L5/α2 subpocket with at least one ring (as 
described in Background and methods). This rigorous filtering resulted in a 
limited number of hybrids (4115) that possessed the required characteristics 
(Table 1). 
 
Description of generated hybrids derived from exclusively inter-
family MED-Portions chemical moieties 
The resulting hybrids have then been filtered for bad geometry and then 
minimized in the query binding site using CHARMm forcefield implemented in 
Discovery Studio 2.0 [28]. Several hybrids having a low energy after 
minimization are shown on Figure 6. They all result from the hybridization of 
inter-family MED-Portions chemical moieties deriving from various ligands 
(Figure 6). All hybrids have been chosen to have an aromatic ring that binds in the 
L5/α 2 pocket. Indeed, except for the bulky ligand (pyrrolo-triazine-4-one 
analogue) in 2gm1 [16], all the other Eg5 co-crystallized ligands from the PDB 
have an aromatic ring of five or six atoms in that pocket. In L5/α 2 pocket several 
conserved residues are involved in the binding of the inhibitors in the solved 
crystal structures of Eg5 from the PDB: Glu116, Glu118, Arg119, Pro137 and 
Leu214 [17]. All those residues are also involved in the predicted binding of the 
selected hybrids (Figure 6). Given the restriction during the hybridisation protocol 
to keep hybrids targeting the HYD pocket, most of the hybrids are interacting with 
the hydrophobic residues Arg221, Leu160, Ile136 and several are forming T-
stacking interactions with Phe239 (Figure 6(a)). Some hybrids are also predicted 
to be involved in H-bond interactions. The hybrid represented in Figure 6(a) 
(Hybrid 1215) has a third group that points toward the solvent like the (S)-
monastrol ethyl ester group. The nitrogen of the amide is predicted to form a H-
bond with the Tyr211. The hybrids represented in Figure 6(b) (Hybrid 969) and 
(c) (Hybrid 1317) are both predicted to form a hydrogen bond with Glu118 
backbone as does the (S)-monastrol. 
 One of the MED-Portions chemical moieties is present in the three 
selected hybrids. It derives from a ligand co-crystallized in the 1q0z PDB 
structure [29] and is very similar to a sub-structure of the Eg5 inhibitor co-
crystallized in 2fme [15]. However it is derived from a very different ligand (10-
decarboxymethylaclacinomycin A) and is co-crystallized with a protein of  the 
aclacinomycin methylesterase (RdmC) family. 
 The hybrids selected at that step are hit-like and can be considered as new 
leads compared to the known PDB ligands that could potentially bind to the 
allosteric site of Eg5. 
 
Comparison of the obtained hybrids to compound libraries with MED-
Search 
Having generated new chemistry for potential kinesin inhibitors, we also checked 
if molecules synthetically accessible were found to be potential ligands targeting 
the HYD pocket. Hybrids generated at the last step were searched in diverse 
chemical libraries including known kinesin inhibitors, commercial libraries like 
the ChemBridge diverset, Maybridge hitfinder and the entire PubChem database 
[23-25]. A new module called MED-Search has been developed for that purpose. 
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As hybrids can still contains Du atoms that were considered as wildcard atoms 
during hybridization, MED-Search needs to deal with that special type of atom. 
To accomplish this task we needed an accurate search algorithm capable to 
treat Du atoms as wildcard atoms that could match any atom type or even nothing. 
Due to a huge amount of comparisons it was crucial to be able to pre-filter crudely 
and very quickly the possible matches. For that purpose, the SCINS representation 
[30,Jenkins, 2004 #27] of the molecules were compared. Only the retained 
matches are submitted to an exact comparison using the SMART representation 
[21]. During the search, if a match is found, the Du atoms of the hybrid are 
replaced by the real atoms of the matched molecule. All the molecules coming out 
of MED-Search do not have Du atoms, and are known, chemically accessible 
molecules. Their 3D coordinates are kept and they are thus aligned in 3D in the 
reference frame of the query binding site. 
We have also generated and searched the Murcko scaffolds computed 
according Bemis and Murcko [31]. For the generation of the scaffolds exocyclic 
double bonds were kept. The results of the comparison are listed in Table 1. 
Amongst the hybrids found exactly in the PubChem library several are 
predicted to bind both in the HYD and in the L5/α 2 pockets (Figure 7). Some 
contain the substructure highlighted in the hybrid description coming from the 
MED-Portion derived from the 1q0z ligand. One of them has been minimized in 
the query binding site, while keeping he protein side chains fixed (Figure 8). This 
molecule does not make hyrdrophobic interaction in the back of the hydrophobic 
pocket but it interacts with all the important residues involved in the binding of 
monastrol analogs and has a different chemistry. It is predicted to be involved in 
two hydrogen bonds with Glu118 and Leu 214. 
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Summary and conclusion 
 
Development of resistance in cancer therapies to drugs that target directly the 
microtubules, as well as their serious side-effects such as neurotoxicity have 
forced the research to chase for other targets that would more specifically inhibit 
the mitotic spindle function. Eg5, a mitotic kinesin exclusively involved in the 
formation and function of the mitotic spindle has attracted interest as an 
anticancer drug target.  
Eg5 is co-crystallized with several inhibitors bound to its allosteric binding 
site. All of them occupy a pocket of this site formed by loop 5 and helix α 2 
(L5/α2), some occupy as well the hydrophobic pocket (HYD) (Figure 2). The 
inhibitors that are binding to both pockets simultaneously have shown sometimes 
a ten fold higher affinity then the ones occupying only the L5/α2 pocket. 
The goal of the present study was to obtain potential new ligands that 
explore this HYD pocket with our MED-SuMo fragment based protocol. We have 
excluded intra-family MED-Portions derived from ligands that occupy the HYD 
pocket and predicted new potential hybrids that would fill simultaneously both 
pockets. The MED-Portions chemical moieties have then been combined with the 
MED-Hybridise software. Some of the latter were found in chemical libraries with 
the MED-Search software and could therefore be tested experimentally. Based on 
structural information, the obtained hybrids bring new ideas about the possible 
scaffolds and chemical functions that could be binding the allosteric site of Eg5 
and occupy both pockets. 
 
 
Background and methods 
 
The results presented in this paper were generated using software developed by 
MEDIT SA, except where stated otherwise. 
 
MED-SuMo technology 
The MED-SuMo technology is described briefly hereafter. For further details as 
well as for the manner of mining the PDB to extract MED-Portions, to populate 
protein surfaces with MED-Portions and to hybridize the MED-Portions refer to 
the papers and the thesis work of Jambon et al. [18, 19, 27] and a recent paper of 
Moriaud et al. describing fragment based drug design protocol derived from our 
core technology [21]. 
 MED-SuMo is derived from the SuMo software [19]. MED-SuMo is able 
to locate similar regions on macromolecular surfaces associated with similar 
chemical groups. It applies a heuristic based on a 3D representation of 
macromolecular surfaces using Surface Chemical Features (SCFs) like, for 
example, H-bond donor, H-bond acceptor, formal positive and negative charges, 
hydrophobic, aromatic, or more specific features like amide and guanidinium. 
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Each feature describes a putative physical interaction including its precise 
geometrical characteristics. The MED-SuMo comparison methodology can be 
divided into two major steps: (1) The Graph Formation: SCFs are displayed on 
the protein structure through a lexicographic analysis of the atoms in the PDB 
files, i.e., a residue is represented by a set of representative SCFs. The 
correspondence between the SCFs and the chemical groups is stored in the MED-
SuMo dictionary. SCFs are assembled into triplets with specific geometric 
characteristics. Such geometric characteristics include edge length, perimeter 
length, and angles. The triplet network is then stored as a graph data structure. 
The triplets are vertices and the edges are connecting adjacent triplets in the 
MED-SuMo database. (2) The Graph Comparison: To compare two graphs, 
MED-SuMo looks for compatible triplets; composed of compatible SCF. These 
triplets are called comparison ‘seeds’. When a seed is detected, MED-SuMo 
extends the comparisons to the vertices of the neighbourhood, until no more 
similarities are found. These comparisons generate the formation of similar 
patches (common groups of SCFs) between two graphs, weighted by the MED-
SuMo score. The MED-SuMo search heuristics is based also on two criteria that 
consider the SCFs 3D positions flexibility and so improve the search for 
compatible graphs. These comparisons are usually performed between a query 
and a database of precompiled graphs. 
 
Steric clash filtering during the MED-SuMo comparison 
During MED-SuMo comparison, a filter of steric clashes is applied. This is 
particularly important for our fragment based approach where we need to find 
relevant MED-Portions chemical moieties that could potentially bind the target. 
This filter is based on the count contacts between the query protein and MED-
Portion chemical moieties.  
 Using SCF superimposition of the query protein and a retrieved hit, atoms 
of MED-Portions are placed in the query binding site. Distances between each 
atom of the MED-Portion chemical moiety, except the Du atoms, and the atoms of 
the query protein are calculated. If the distance between two atoms is shorter than 
the sum of their Van der Waals radii weighted by a coefficient a contact is 
registered. This coefficient was set to 0.8.  This value was was empirically 
determined to allow flexibility in the clash detection. The filter can be set on the 
number of atoms clashing or on the total number of clashes for the given MED-
Portions. Finally, if the number of clashes is greater than a user defined value, the 
MED-Portion is excluded. 
 In this study, only the MED-Portions chemical moieties that exhibit more 
than ten steric clashes with the query protein are discarded. 
 
MED-Portion definition 
MED-Portions are the MED-SuMo representation of protein-fragment patterns 
obtained by fragmentation of the protein-ligand structures using the MED-
Fragmentor [21]. MED-Portions are defined by several criteria: (1) a chemical 
moiety where atoms are topologically matching a molecule of less then 250 Da 
from molecular libraries. Therefore, these molecules are expected to be 
synthetically accessible molecules or building blocks, (2) open valences filled by 
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Du atoms that indicate where it was connected in the original ligand, and (3) the 
protein interaction surface surrounding that chemical moiety described by the 
SCFs. The pre-calculated MED-SuMo fragment data base contains 340 888 
“binding-sites” and thus 340 888 MED-Portions. MED-Portion chemical moieties 
are collected in the reference frame of the query and form a pool which is used to 
generate new 3D hybrid compounds by hybridization. 
 
Custom dictionary database 
To use the structural information provided by water molecules crystallized into 
the binding sites, the MED-SuMo dictionary was modified. Indeed, MED-SuMo 
software allows the advanced user to modify the dictionary of SCF definitions by 
editing a text file. 
Given the potential importance of the water molecules for the considered target, 
we have taken them into account. This allows them to match with either water 
molecules, or H-bond donors and acceptors on the hit protein structure. 
In the classical MED-SuMo dictionary, H-bond donor and acceptor SCFs have a 
defined orientation. The H-bond donor SCF is also projected to the location of a 
potential H-bond acceptor. For water molecules it is not possible to derive any 
orientation or projection for the H-bond donor or acceptor groups. Therefore we 
added two new ponctual geometrical variant of H-bond acceptor and H-bond 
donor in the dictionary syntax. Both are neither orientated nor projected. In this 
new version of the MED-SuMo dictionary, the water molecules are considered as 
part of the receptor and are described with one H-bond acceptor and H-bond 
donor. 
In MED-SuMo only chemical groups of the same type can be compared 
and possibly considered as equivalent. One aim of the new dictionary is to be able 
to match the H-bond donor and/or acceptor of the water molecules with similar 
groups on the proteins. Therefore former orientated H-bond donors and acceptors 
on the protein structure are replaced by the new punctual H-bond donor and 
acceptor. Once the SCFs are positioned on the macromolecular structure their 
positions and orientations are filtered. In the default MED-SuMo configuration a 
filtering step discards any SCFs likely to be involved in intra-molecular hydrogen 
bonds. With the new dictionary this filter is skipped. However the SCFs too 
buried to interact with a potential ligand are still discarded. 
 
Selection of collected MED-Portions 
From the collected MED-Portions we eliminated the ones derived from the Eg5 
ligands that are located in the targeted hydrophobic pocket (2gm1, 2g1q, 2q2y, 
2uyi, 2uym, 2pg2, 2q2z, 1yrs, 2fl6, 2ieh, 2fky, 2fl2, 3cj0). MED-Portions derived 
from three structures of Eg5 were kept, since their ligands are not positioned in 
the HYD pocket: 1x88, 2fme and 1q0b. The selected MED-Portions’ atoms were 
typed with OpenBabel [32]. 
 
Selection of seeds 
To create new ligands that would bind simultaneously the targeted HYD and the 
L5/α2 pocket, we selected a sub-list of rings derived from the retrieved MED-
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Portions chemical moieties that explored these pockets as the starting points, the 
seeds. The seeds were selected as follows. We fragmented the retrieved MED-
Portions in rings and linker parts. Then we filtered the rings, to keep only those 
that had at least one carbon atom inside one of the pockets. The emplacement of 
this atom was selected at 3 Å around the deepest one buried in the L5/α2 pocket of 
the 1x88 ligand and deepest one buried in the HYD pocket of the mon-97 ligand 
from the 2ieh PDB code structure as it was placed inside the 1x88 PDB code 
structure binding pocket after the superposition of the two structures by MED-
SuMo (Figure 9). The selected rings were decorated with Du atoms at every 
possible position defined by implicit hydrogen atoms. 
 
Hybridization parameters and substructure filtering  
We applied 5 hybridization steps with the Chain Combine algorithm of MED-
Hybridise [21]. The basic principle of Chain Combine is to look for overlapping 
bonds between a pair of aligned MED-Portions. The Du atoms of the MED-
Portions are considered as wildcard atoms during the hybridization steps. 
 We have hybridized the seeds to the whole list of selected MED-Portions 
during the first step. Then we hybridized the seeds to the molecules obtained in 
the previous step. During steps 2 to 5 we used the seeds, without Du atoms for the 
substructure 3D filtering, by keeping only the hybrids that were superstructures of 
the one of those seeds. After each step we filtered the obtained hybrids for 3D 
duplicates (RMSD 2.0 during the first step, RMSD 4.0 during the 2nd to the 4th 
steps, and RMSD 6.0 afterwards). These 4841 molecules have been submitted to 
the MED-Search module as explained later. 
In parallel, several filtering steps were applied, molecules with intra-
molecular clashes and elevated strain energy, the ones containing a phosphate 
atom or a ribose are discarded. The remaining hybrids were minimized in the 
binding site of the query structure with the CHARMm forcefield included in 
Discovery Studio 2.0 [28]. The query structure is 1x88 used for the MED-SuMo 
run after removing all ligands and water molecules. During the minimization the 
receptor is considered rigid. 
 
MED-Search module 
The aim of the MED-Search software is to search the designed hybrid molecules 
that contain in many cases dummy atoms, versus a large compound library rapidly 
and accurately.  It uses a two-step algorithm. 
 The first step rapidly skips molecules that can be trivially seen to not 
match without discarding false negatives. For reasons of efficiency, this step is 
performed via comparison of a novel mini-fingerprint that encode molecules' 
scaffold structures. The design of this mini fingerprint was inspired by the 
Novartis SCINS classifier [30, 33]. It consists of an array of thirteen integer 
values, corresponding to the thirteen values in the SCINS classifier. The queries 
are read from the input file and SCINS fingerprints for these molecules are 
generated during the first loop of comparison against the first target molecule. 
Molecules are further compared with an exact comparison only when their 
Tanimoto similarity metric exceeds a 0.99 threshold value. 
 The second step is the exact structure search that analyses the connectivity 
of the compared molecules and then compares corresponding atom pairs. Two 
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atoms are treated as matching if they have the same atom type (Sybyl-style atom 
type), if they are or not in a ring and if they are or not aromatic. These rules apply 
only to real atoms. Du atoms are considered as wildcard atoms and can match any 
atom or even nothing.  
At this stage, Du atoms can be replaced with real atom types to complete 
the match. During the comparison, the algorithm tries first to superimpose the 
non-Du atoms of the query. If the exact matching is successful, then the mapping 
of Du atoms is done and they are replaced according to the corresponding atom in 
the hit. Where there is no possible match, the Du atom can be deleted. 
The exact structure of 3077 hybrids were compared to the chemical libraries (20 
million compounds) with MED-Search. This comparison took forty hours on eight 
CPUs (2 Xeon Quad Core 5335, 16 GB RAM).  
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Fig.1 2D representation of known Eg5 inhibitors. The 3,5-diaryl-4,5-dihydropyrazole (a) is a 
potent and selective inhibitor of Eg5 that is active in cells at low nanomolar concentrations. It was 
identified in a high throughput screening by Merck (Cox, et al. 2005). X-ray crystallographic 
evidence is presented which demonstrates that this inhibitor bind the same allosteric pocket as the 
monastrol (b) and mon-97 (c) of Eg5 that is distant from the nucleotide and microtubule binding 
sites. Further studies showed that by appending a propylamine substituent at the C5 carbon of a 
dihydropyrazole core, lead to compounds with increased potency and aqueous solubility (d and e) 
 
Fig.2 (a) View of the Eg5 binding site surface from the 1x88 PDB structure showing the co-
cristallized monastrol (green) and the mon-97 (clear blue) from the 2ieh PDB structure, retrieved 
from the superposition of the two protein structures with MED-SuMo. Both ligands occupy the 
sub-pocket formed by loop 5 (L5) and the helix α 2 (α 2). The mon-97 occupies as well the 
hydrophobic pocket HB shown in (b) Grey: hydrophobic, blue: hydrophilic 
 
Fig.3 MED-SuMo core algorithm: graph creation-comparison. 1. The protein molecular structure 
is scanned and mapped to a dictionary of physicochemical/geometric constructors that detect the 
MED-SuMo Surface Chemical Features (SCFs, represented by colored circles). 2. The geometric 
rules are applied to build a network of triplets (green triangle). 3. This network is transposed into a 
graph data structure. 4. The resulting graph is compared to the precompiled database of similarly 
constructed graphs 
 
Fig.4 Query definition. The binding site is defined at 10 Å around every atom of the (S)-monastrol 
(NAT) of the 1x88 structure, MED-SuMo detects 187 Surface Chemical Futures (SCF, described 
in Background and methods section) (a). By building the query with these SCFs, the graph 
contains 6090 triplets (b) which are then submitted to the database 
 
Fig.5 Hybridisation seeds from the HYD pocket (salmon). The seeds used in the hybridization 
steps have been selected as described in Background and methods. Green: monastrol ligand from 
the 1x88 structure. Blue: mon-97 ligand from the 2ieh structure 
 
Fig.6 Examples of the selected hybrids and the MED-SuMo chemical moieties that have been used 
for their formation presented in 3D coordinates, inside the 1x88 allosteric binding site. In L5/α 2 
pocket several conserved residues are involved in the binding to the inhibitor in all the crystal 
structures of Eg5 from the PDB: Glu116, Glu118, Arg119, Pro137 and Leu214. All those residues 
are also involved in the predicted binding of the selected hybrids. In the HYD pocket, all the 
hybrids are interacting with the hydrophobic residues Arg221, Leu160, Ile136 and especially are 
forming T-stacking interacting with Phe239. Hybrid 1215 represented in (a) has a third group that 
points toward the solvent like the (S)-monastrol ethyl ester group. The nitrogen of the amide is 
predicted to form a hydrogen bond with the Tyr211. Hybrid 1317 represented in (b) and hybrid 
969 (c) are both predicted to form a hydrogen bond with Glu118 background as does the (S)-
monastrol. For each of the hybrids above MED-Portions were derived from the following PDB 
structures : (d) 1fo4 in blue, 1n78 in orange, 1q0z in green and 2ox0 in red; (e) 1n78 in dark blue, 
1r3w in pink, 1q0z in purple and 1oo5 in clear blue (f) 1r3w in clear blue, 1q0z in orange and 1eqb 
in green 
1fo4: xanthine dehydrogenase, ligand 2-hydroxybenzoic acid   
1n78: glutamyl-trna synthetase, ligand glutamol-amp   
1q0z: aclacinomycin methylesterase, ligand 10-decarboxymethylaclacinomycin a 
2ox0: histone demethylase, ligand n-oxalyolglycine   
1r3w: uroporphyrinogen decarboxylase, ligand coproporphyrin iii 
1oo5: nitroreductase prodrug-activating system, ligand flavin mononucleotide   
1eqb: serine hydroxymethyltransferase, ligand 5-formyl-6-hydrofolic acid 
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Fig.7 Examples of hybrids found in PubChem with MED-Search. These molecules should be 
considered as scaffold to be decorated as they are often too hydrophobic to be tested. 
 
Fig.8 (a) Example of a hybrid that matched a PubChem molecule. This hybrid is derived from 
three MED-Portions represented in their 3D coordinates (b) derived from the following PDB 
structures: 3pax in orange, 1q0z in green and 1gos in red 
3pax: poly (ADP-ribose) polymerase, ligand 3-methoxybenzamide 
1q0z: aclacinomycin methylesterase, ligand 10-decarboxymethylaclacinomycin a 
1gos: human monoaminne oxidase b, ligand flavin-adenine dinucleotide 
 
Fig.9 Definition of the filtering options on a C-atom substructure inside the HYD pocket (violet 
sphere on the right) and the L5/α2 pockets (violet sphere on the left) of the Eg5 binding site 
surface from the 1x88 PDB structure. The ligand from the 1x88 structure, monastrol is represented 
in green. The mon-97 ligand (pale blue) from the 2ieh PDB structure that fills the HB pocket is 
represented in 3D coordinates after the alignment of the kinesin structures of 2ieh with 1x88 with 
MED-SuMo 
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Table 1 Statistics on the hybrids. Hybrids were generated as described. They contain Du atoms 
and are filtered for 3D duplicates and 2D duplicates. The 2D filtered hybrids have been submitted 
to MED-Search and the listed sources of molecules. The numbers of found molecules represent the 
number of molecules in a particular library that matched the hybrids.  Wildcard can  match nothing 
or any atom type 
 
Hybrid count (unique 3D) 4115 
Hybrid count (unique 2D, Du wildcard) 1417 
Scaffold (SC, unique 3D) 903 
Scaffold (unique 2D, Du wildcard)  814 
  
Hybrids found in PubChem 3390 
Hybrids found in the PDB 2 
Hybrids found in the chemical libraries (Chembridge diverset, Maybridge 
hitfinder) 
114 
Hybrids found in the a list of inhibitors (BindingDB) 6 
 
  
SC found in PubChem 293 
SC found in the PDB 15 
Hybrids found in the chemical libraries (Chembridge diverset, Maybridge 
hitfinder) 
57 
Hybrids found in the a list of inhibitors (BindingDB) 2 
 
 
